[go: up one dir, main page]

PL2262493T3 - Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu - Google Patents

Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu

Info

Publication number
PL2262493T3
PL2262493T3 PL09717048T PL09717048T PL2262493T3 PL 2262493 T3 PL2262493 T3 PL 2262493T3 PL 09717048 T PL09717048 T PL 09717048T PL 09717048 T PL09717048 T PL 09717048T PL 2262493 T3 PL2262493 T3 PL 2262493T3
Authority
PL
Poland
Prior art keywords
belinostat
methods
continuous infusion
treatment employing
prolonged continuous
Prior art date
Application number
PL09717048T
Other languages
English (en)
Inventor
Maxwell Sehested
Peter Buhl Jensen
Nis Nissen
Original Assignee
Onxeo Dk Branch Of Onxeo S A France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo Dk Branch Of Onxeo S A France filed Critical Onxeo Dk Branch Of Onxeo S A France
Publication of PL2262493T3 publication Critical patent/PL2262493T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL09717048T 2008-03-07 2009-03-06 Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu PL2262493T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat
EP09717048.4A EP2262493B1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (1)

Publication Number Publication Date
PL2262493T3 true PL2262493T3 (pl) 2015-08-31

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09717048T PL2262493T3 (pl) 2008-03-07 2009-03-06 Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu

Country Status (14)

Country Link
US (1) US20110003777A1 (pl)
EP (1) EP2262493B1 (pl)
JP (1) JP5615189B2 (pl)
CN (1) CN102083428A (pl)
AU (1) AU2009220942B2 (pl)
CA (1) CA2717207A1 (pl)
DK (1) DK2262493T3 (pl)
EA (1) EA022880B1 (pl)
ES (1) ES2536208T3 (pl)
MX (1) MX2010009642A (pl)
PL (1) PL2262493T3 (pl)
PT (1) PT2262493E (pl)
SI (1) SI2262493T1 (pl)
WO (1) WO2009109861A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
CN109077995A (zh) * 2012-04-27 2018-12-25 太阳医药工业有限公司 即可灌注的吉西他滨溶液
CN103839548B (zh) * 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
JP2002527449A (ja) * 1998-10-13 2002-08-27 藤沢薬品工業株式会社 環状テトラペプチド化合物およびその用途
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6541661B1 (en) * 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
EP2083005A1 (en) * 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002030879A2 (en) * 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
PL368129A1 (pl) * 2001-08-09 2005-03-21 Ono Pharmaceutical Co, Ltd. Pochodne kwasu karboksylowego i środek farmaceutyczny zawierający te pochodne jako składnik aktywny
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7041699B2 (en) * 2002-01-11 2006-05-09 Matthias Rath Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EP2322160A1 (en) * 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
PT1663194E (pt) * 2003-08-26 2010-07-06 Merck Hdac Res Llc Utilizaã†o de saha para o tratamento de mesotelioma
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
EP1725873B1 (en) * 2004-02-27 2009-07-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry.
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
EP1787657A1 (en) * 2004-08-06 2007-05-23 Ono Pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
WO2006060382A2 (en) * 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
KR101346886B1 (ko) * 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
CA2596210C (en) * 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
ES2380887T3 (es) * 2005-05-13 2012-05-21 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
JP2009504751A (ja) * 2005-08-19 2009-02-05 アメリカ合衆国 ヒストンデアセチラーゼ阻害薬の局所製剤及びその使用方法
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
US8828392B2 (en) * 2005-11-10 2014-09-09 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
KR20080103977A (ko) * 2006-02-22 2008-11-28 4에스체 악티엔게젤샤프트 Ｅｇ５ 키네신 조절자로서 인돌로피리딘
US8530493B2 (en) * 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
WO2008011603A2 (en) * 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) * 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Also Published As

Publication number Publication date
MX2010009642A (es) 2010-09-22
PT2262493E (pt) 2015-06-02
AU2009220942A8 (en) 2012-08-30
CA2717207A1 (en) 2009-09-11
WO2009109861A1 (en) 2009-09-11
AU2009220942A1 (en) 2009-09-11
JP2011513378A (ja) 2011-04-28
EA201070913A1 (ru) 2011-04-29
US20110003777A1 (en) 2011-01-06
CN102083428A (zh) 2011-06-01
EP2262493B1 (en) 2015-02-25
DK2262493T3 (en) 2015-04-27
SI2262493T1 (sl) 2015-07-31
EA022880B1 (ru) 2016-03-31
AU2009220942B2 (en) 2015-05-28
JP5615189B2 (ja) 2014-10-29
EP2262493A1 (en) 2010-12-22
HK1152247A1 (en) 2012-02-24
ES2536208T3 (es) 2015-05-21

Similar Documents

Publication Publication Date Title
ZA201006648B (en) Methods of treatment
NO2016023I1 (no) Glycerol fenylbutyrat
GB0802116D0 (en) Treatment
SI3005986T1 (sl) Infuzija zdravil
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
GB0811992D0 (en) Treatment
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
EP2164494A4 (en) Methods of Treatment
SI2262493T1 (sl) Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP2303284A4 (en) METHOD FOR TREATING BIPOLAR DISORDER
GB0723100D0 (en) Treatment of HFnEF
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB0814043D0 (en) The treatment of skin disorders
GB2465211B (en) Treatment Solution
SI2330892T1 (sl) Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak
GB0700969D0 (en) Methods of treatment
GB0809319D0 (en) The treatment of puritus
GB0801410D0 (en) Therapeutic intervention
GB0804454D0 (en) New therapeutic use
GB0817738D0 (en) New therapeutic use
GB0817739D0 (en) New therapeutic use
GB0817740D0 (en) New therapeutic use
GB0816979D0 (en) New therapeutic use